Trials / No Longer Available
No Longer AvailableNCT02147951
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma.
Detailed description
Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma that may not meet the eligibility criteria to enroll in another ongoing Talimogene Laherparepvec study or do not have access to enroll in an ongoing Talimogene Laherparepvec study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talimogene Laherparepvec | Up to 4ml of talimogene laherparepvec per cycle visit |
Timeline
- First posted
- 2014-05-28
- Last updated
- 2016-03-01
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02147951. Inclusion in this directory is not an endorsement.